NEW YORK, April 27, 2015 /PRNewswire/ -- Cocrystal Pharma Inc. (OTCQB: COCP) a Washington-State based pharmaceutical company working to develop antiviral therapeutics as treatments for serious and/or chronic viral diseases, expects to begin clinical studies on several of its antiviral therapeutic treatments in 2015. The company has several drugs in various stages of development for the treatment of Hepatitis C, Influenza, Norovirus, Dengue Fever and others.
The company is backed by Opko Health, who currently has an 8% stake in the company. This relationship should be beneficial for COCP as they work to streamline their products into clinical studies.
For analyst comments and recommendation on Cocrystal Pharma Inc. please follow the link. There is no cost obligation required to view analyst brief.
Copy and paste to browser may be required.
This report was prepared for informational purposes only. Affiliated parties involved with producing and issuing this report have not been compensated in any form by profiled company. A full disclaimer can be found by viewing the full analyst report.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is written and authored by a 3rd party research analyst. However, we are only human and make mistakes. If you notice any errors or omissions, please notify us below.
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.
SOURCE BrokerBank Securities, Inc.